Allosteric Modulation

A receptor has an orthosteric site, where its endogenous ligand binds, and often one or more allosteric sites elsewhere on the protein. A modulator occupying an allosteric site changes the conformational landscape, so the orthosteric ligand binds more tightly or signals more strongly (a positive modulator) or does the opposite (a negative one). The effect is defined by a cooperativity factor, which means it saturates: once every allosteric site is filled, the shift stops, giving these drugs an intrinsic ceiling that orthosteric agonists lack.

The class is well populated. Benzodiazepines are positive modulators at the GABA-A receptor, doing nothing without GABA present. Cinacalcet is a positive modulator of the calcium-sensing receptor used in hyperparathyroidism. Maraviroc blocks HIV entry as a negative modulator at CCR5 rather than by competing with a chemokine. On the peptide side, small-molecule modulators of the GLP-1 receptor have been used as laboratory tools for years, exploiting a site far from the peptide-binding groove.

The attraction is preservation of pattern and selectivity. A pure modulator amplifies or damps signalling only where and when the endogenous ligand is already released, so the physiological rhythm survives, and the ceiling limits how far an overdose can push the system. Allosteric pockets are also less conserved across receptor subtypes than orthosteric ones, which makes subtype-selective drugs easier to find.

Two traps recur. Probe dependence means a modulator characterised against one agonist may not modulate another at the same receptor, so a number measured with a synthetic probe may not transfer to the native hormone. And a modulator with no intrinsic activity of its own does nothing at all when tone is absent, so an effect seen under stimulated conditions can vanish in a fasting or resting state.